12/20
01:30 am
veru
Low
Report
12/18
08:05 am
veru
Veru (NASDAQ:VERU) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $25.00 price target on the stock.
Medium
Report
Veru (NASDAQ:VERU) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $25.00 price target on the stock.
12/18
06:08 am
veru
Veru (NASDAQ:VERU) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Medium
Report
Veru (NASDAQ:VERU) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
12/17
02:18 pm
veru
Veru Inc (VERU) Q4 2025 Earnings Call Highlights: Strategic Shifts and Financial Challenges [Yahoo! Finance]
Low
Report
Veru Inc (VERU) Q4 2025 Earnings Call Highlights: Strategic Shifts and Financial Challenges [Yahoo! Finance]
12/17
12:03 pm
veru
Veru Inc. (VERU) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Veru Inc. (VERU) Q4 2025 Earnings Call Transcript [Seeking Alpha]
12/17
06:30 am
veru
Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress
Medium
Report
Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress
12/10
09:19 am
veru
Veru to Report Fiscal Year 2025 Financial Results on December 17th [Yahoo! Finance]
Low
Report
Veru to Report Fiscal Year 2025 Financial Results on December 17th [Yahoo! Finance]
12/10
08:30 am
veru
Veru to Report Fiscal Year 2025 Financial Results on December 17th
Neutral
Report
Veru to Report Fiscal Year 2025 Financial Results on December 17th
12/4
07:03 pm
veru
Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop [Yahoo! Finance]
Medium
Report
Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop [Yahoo! Finance]
12/4
08:30 am
veru
Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop
Medium
Report
Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop
11/17
02:54 pm
veru
Global Contraceptive Devices Market is Set to Accelerate at a CAGR of ~6% by 2032, as Demand for Advanced Birth Control Solutions Rises | DelveInsight [Yahoo! Finance]
Low
Report
Global Contraceptive Devices Market is Set to Accelerate at a CAGR of ~6% by 2032, as Demand for Advanced Birth Control Solutions Rises | DelveInsight [Yahoo! Finance]
10/31
08:30 am
veru
Veru to Present Two Abstracts at ObesityWeek 2025
Low
Report
Veru to Present Two Abstracts at ObesityWeek 2025
10/30
08:00 am
veru
Veru Announces Pricing of $25 Million Public Offering
Medium
Report
Veru Announces Pricing of $25 Million Public Offering
10/29
04:01 pm
veru
Veru Announces Proposed Public Offering
High
Report
Veru Announces Proposed Public Offering
9/27
08:45 am
veru
Onconetix announces financing through private placement, debt settlement [Yahoo! Finance]
Low
Report
Onconetix announces financing through private placement, debt settlement [Yahoo! Finance]
9/26
08:44 am
veru
Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc. [Yahoo! Finance]
Medium
Report
Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc. [Yahoo! Finance]